The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis
Open accessAbstract
Axonal degeneration is an important determinant of progressive neurological disability in multiple sclerosis (MS). Thus, therapeutic approaches promoting neuroprotection could aid the treatment of progressive MS. Here, we used what we believe is a novel water-soluble fullerene derivative (ABS-75) attached to an NMDA receptor antagonist, which combines antioxidant and anti-excitotoxic properties, to block axonal damage and reduce disease progression in a chronic progressive EAE model. Fullerene ABS-75 treatment initiated after disease onset reduced the clinical progression of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG). Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord. Fullerene ABS-75 halted oxidative injury, CD11b+ infiltration, and CCL2 expression in the spinal cord of mice without interfering with antigen-specific T cell responses. In vitro, fullerene ABS-75 protected neurons from oxidative and glutamate-induced injury and restored glutamine synthetase and glutamate transporter expression in astrocytes under inflammatory insult. Glutamine synthetase expression was also increased in the white matter of fullerene ABS-75-treated animals. Our data demonstrate the neuroprotective effect of treatment with a fullerene compound combined with a NMDA receptor antagonist, which may be useful in the treatment of progressive MS and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death
Boje, K. M., & Arora, P. K. (1992) · Brain Research · doi:10.1016/0006-8993(92)91004-x · Cited by 944
Bal-Price, A., & Brown, G. C. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06480.2001 · Cited by 686
Bjartmar, C., Wujek, J. R., & Trapp, B. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00069-2 · Cited by 573
Selective targeting of an antioxidant to mitochondria
Smith, R. A. J., Porteous, C. M., Coulter, C. V., & Murphy, M. P. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00543.x · Cited by 466
Neurodegenerative disorders: the role of peroxynitrite
Torreilles, F., Salman-Tabcheh, S., Guérin, M.-C., & Torreilles, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00014-4 · Cited by 430
Hill, K. E., Zollinger, L. V., Watt, H. E., Carlson, N. G., & Rose, J. W. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.02.005 · Cited by 158
Sperfeld (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199911)46:5 · Cited by 2
Cited by
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Self-citationThe Role of Astrocytes in CNS Inflammation
Giovannoni, F., & Quintana, F. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.07.007 · Cited by 651
Self-citationMechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Multiple sclerosis: experimental models and reality
Lassmann, H., & Bradl, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1631-4 · Cited by 525
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation
Mayo, L., Trauger, S. A., Blain, M., Nadeau, M., Patel, B., Alvarez, J. I., Mascanfroni, I. D., Yeste, A., Kivisäkk, P., Kallas, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3681 · Cited by 472
Self-citationMolnarfi, N., Schulze-Topphoff, U., Weber, M. S., Patarroyo, J. C., Prod’homme, T., Varrin-Doyer, M., Shetty, A., Linington, C., Slavin, A. J., Hidalgo, J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130699 · Cited by 418
Fullerene: biomedical engineers get to revisit an old friend
Goodarzi, S., Da Ros, T., Conde, J., Sefat, F., & Mozafari, M. (2017) · Materials Today · doi:10.1016/j.mattod.2017.03.017 · Cited by 368
Wilms, H., Sievers, J., Rickert, U., Rostami-Yazdi, M., Mrowietz, U., & Lucius, R. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-30 · Cited by 344
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 344
Self-citationSiffrin, V., Radbruch, H., Glumm, R., Niesner, R., Paterka, M., Herz, J., Leuenberger, T., Lehmann, S. M., Luenstedt, S., Rinnenthal, J. L., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.018 · Cited by 325
Radical changes in multiple sclerosis pathogenesis
van Horssen, J., Witte, M. E., Schreibelt, G., & de Vries, H. E. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.011 · Cited by 322
Multiple sclerosis animal models: a clinical and histopathological perspective
Kipp, M., Nyamoya, S., Hochstrasser, T., & Amor, S. (2017) · Brain Pathology · doi:10.1111/bpa.12454 · Cited by 226
Review: Mitochondria and disease progression in multiple sclerosis
Mahad, D., Lassmann, H., & Turnbull, D. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00987.x · Cited by 193
Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis
Vogt, J., Paul, F., Aktas, O., Müller‐Wielsch, K., Dörr, J., Dörr, S., Bharathi, B. S., Glumm, R., Schmitz, C., Steinbusch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21719 · Cited by 157
Pathomechanisms underlying X-adrenoleukodystrophy: A three-hit hypothesis
Singh, I., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00392.x · Cited by 148
In vivo evidence of glutamate toxicity in multiple sclerosis
Azevedo, C. J., Kornak, J., Chu, P., Sampat, M., Okuda, D. T., Cree, B. A., Nelson, S. J., Hauser, S. L., & Pelletier, D. (2014) · Annals of Neurology · doi:10.1002/ana.24202 · Cited by 100
Bernal-Chico, A., Canedo, M., Manterola, A., Victoria Sánchez-Gómez, M., Pérez-Samartín, A., Rodríguez-Puertas, R., Matute, C., & Mato, S. (2015) · Glia · doi:10.1002/glia.22742 · Cited by 87
Guo, F., Maeda, Y., Ko, E. M., Delgado, M., Horiuchi, M., Soulika, A., Miers, L., Burns, T., Itoh, T., Shen, H., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4073-11.2012 · Cited by 76
Therapeutics, imaging and toxicity of nanomaterials in the central nervous system.
Nunes, A., Al-Jamal, K. T., & Kostarelos, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.026 · Cited by 75
“Recent studies using a fullerene derivative (ABS-75) conjugated with glutamate receptor antagonists have demonstrated the capacity of the system to reduce the clinical progression of chronicmultiple sclerosis (experimental autoimmune encephalitis murinemodel) [84].”
BackgroundMicroglia suppress the secondary progression of autoimmune encephalomyelitis
Tanabe, S., Saitoh, S., Miyajima, H., Itokazu, T., & Yamashita, T. (2019) · Glia · doi:10.1002/glia.23640 · Cited by 52
Characterization of brain lesions in a mouse model of progressive multiple sclerosis
Levy, H., Assaf, Y., & Frenkel, D. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.08.017 · Cited by 50
“In this model, mice are immunized with myelin antigen and develop different levels of paralysis that can be monitored (Basso et al., 2008).”
Self-citationRegional regulation of glutamate signaling during cuprizone-induced demyelination in the brain
Azami Tameh, A., Clarner, T., Beyer, C., Atlasi, M. A., Hassanzadeh, G., & Naderian, H. (2013) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2013.03.004 · Cited by 43
Jackson, S. J., Lee, J., Nikodemova, M., Fabry, Z., & Duncan, I. D. (2009) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e3181a41d23 · Cited by 38
Modelling MS: Chronic-Relapsing EAE in the NOD/Lt Mouse Strain
Dang, P. T., Bui, Q., D’Souza, C. S., & Orian, J. M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_378 · Cited by 35
Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model
Baker, D., Nutma, E., O'Shea, H., Cooke, A., Orian, J. M., & Amor, S. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.792 · Cited by 21
“…substrate for slow progressive nerve loss in MS. 11 However, the loss of axons and myelin, accumulation of microglial activation and gliosis reported in progressive EAE models, 24–31 is not qualitatively different from that found following the accumulation of disability from relapsing EAE in mice.”
Buonvicino, D., Ranieri, G., Pratesi, S., Guasti, D., & Chiarugi, A. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113065 · Cited by 18
Buonvicino, D., Ranieri, G., Pratesi, S., Gerace, E., Muzzi, M., Guasti, D., Tofani, L., & Chiarugi, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15058 · Cited by 15
Characterization of pathological stages in a mouse model of progressive multiple sclerosis
Hamano, S., Yoshimizu, T., Mori, M., Iida, A., & Yamashita, T. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.01.009 · Cited by 3
Metadata
- Authors
- Basso, A. S., Frenkel, D., Quintana, F. J., Costa-Pinto, F. A., Petrovic-Stojkovic, S., Puckett, L., Monsonego, A., Bar-Shir, A., Engel, Y., Gozin, M., & Weiner, H. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-04-01
- Volume
- 118
- Issue
- 4
- Pages
- 1532-1543
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2136557471
- Cited by
- 237
- References
- 8
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.